National Bank Of Canada Gracell Biotechnologies Inc. Transaction History

National Bank Of Canada

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 24, 2023	SELL	$2.08 - $3.96 $873 - $1,663	-420 Reduced 25.49%	1,228 $0
Q3 2022 Oct 13, 2022	SELL	$2.08 - $5.15 $416 - $1,030	-200 Reduced 10.82%	1,648 $5,000
Q2 2022 Jul 28, 2022	SELL	$1.95 - $5.5 $136,890 - $386,100	-70,200 Reduced 97.44%	1,848 $10,000
Q1 2022 May 05, 2022	SELL	$1.83 - $5.52 $301,340 - $908,961	-164,667 Reduced 69.56%	72,048 $168,000
Q4 2021 Jan 24, 2022	BUY	$5.65 - $14.9 $1.34 Million - $3.53 Million	236,715 New	236,715 $1.43 Million

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

Stay updated on National Bank Of Canada with notifications on news.